Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review

References

• SwerdlowSHCampoEPileriSAThe 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood20161272375239026980727
   PubMed Web of Science ®Google Scholar
• VoseJArmitageJWeisenburgerDInternational T-Cell Lymphoma ProjectInternational peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomesJ Clin Oncol2008264124413018626005
   PubMed Web of Science ®Google Scholar
• MakitaSTobinaiKDisease oriented treatment of T-cell lymphomaHematol Oncol201735545928591416
   PubMed Web of Science ®Google Scholar
• MakitaSTobinaiKClinical features and current optimal management of natural killer/T-cell lymphomaHematol Oncol Clin North Am20173123925328340876
   PubMed Web of Science ®Google Scholar
• ReimerPRüdigerTGeissingerEAutologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter studyJ Clin Oncol20092710611319029417
   PubMed Web of Science ®Google Scholar
• KitaharaHMaruyamaDMaeshimaAMPrognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatmentAnn Hematol20179641142027928587
   PubMed Web of Science ®Google Scholar
• MakVHammJChhanabhaiMSurvival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivorsJ Clin Oncol2013311970197623610113
   PubMed Web of Science ®Google Scholar
• O’ConnorOAProBPinter-BrownLPralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyJ Clin Oncol2011291182118921245435
   PubMed Web of Science ®Google Scholar
• PiekarzRLFryeRTurnerMPhase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaJ Clin Oncol2009275410541719826128
   PubMed Web of Science ®Google Scholar
• WhittakerSJDemierreMFKimEJFinal results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphomaJ Clin Oncol2010284485449120697094
   PubMed Web of Science ®Google Scholar
• CoiffierBProBPrinceHMRomidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesJ Hematol Oncol201471124456586
   PubMed Web of Science ®Google Scholar
• MaruyamaDTobinaiKOguraMRomidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics studyInt J Hematol201710665566528664499
   PubMed Web of Science ®Google Scholar
• ProBAdvaniRBricePBrentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II studyJ Clin Oncol2012302190219622614995
   PubMed Web of Science ®Google Scholar
• HorwitzSMAdvaniRHBartlettNLObjective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotinBlood20141233095310024652992
   PubMed Web of Science ®Google Scholar
• PrinceHMKimYHHorwitzSMBrentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialLancet201739055556628600132
   PubMed Web of Science ®Google Scholar
• ShiYDongMHongXResults from a multicenter, openlabel, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphomaAnn Oncol2015261766177126105599
   PubMed Web of Science ®Google Scholar
• MakitaSTobinaiKMogamulizumab for the treatment of T-cell lymphomaExpert Opin Biol Ther2017171145115328649848
   PubMed Web of Science ®Google Scholar
• OguraMIshidaTHatakeKMulticenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphomaJ Clin Oncol2014321157116324616310
   PubMed Web of Science ®Google Scholar
• ZinzaniPLKarlinLRadfordJEuropean phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphomaHaematologica2016101e407e41027418646
   PubMed Web of Science ®Google Scholar
• DuvicMPinter-BrownLCFossFMPhase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphomaBlood20151251883188925605368
   PubMed Web of Science ®Google Scholar
• MannBSJohnsonJRHeKVorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphomaClin Cancer Res2007132318232217438089
   PubMed Web of Science ®Google Scholar
• O’ConnorOAHorwitzSMassziTBelinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) studyJ Clin Oncol2015332492249926101246
   PubMed Web of Science ®Google Scholar
• KimBKChaSParksREJrPurine nucleoside phosphorylase from human erythrocytes. I. Purification and propertiesJ Biol Chem1968243176317705651328
   PubMed Web of Science ®Google Scholar
• GiblettERAmmannAJWaraDWSandmanRDiamondLKNucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunityLancet197511010101348676
   PubMed Web of Science ®Google Scholar
• CarsonDAKayeJSeegmillerJELymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s)Proc Natl Acad Sci U S A19777456775681202960
   PubMed Web of Science ®Google Scholar
• CarsonDAKayeJMatsumotoSSeegmillerJEThompsonLBiochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell linesProc Natl Acad Sci U S A19797624302433313056
   PubMed Web of Science ®Google Scholar
• KazmersISMitchellBSDadonnaPEInhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblastsScience1981214113711396795718
   PubMed Web of Science ®Google Scholar
• GilbertsenRBJosyulaUSircarJCComparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955Biochem Pharmacol1992449969991530667
   PubMed Web of Science ®Google Scholar
• ViegasTXOmuraGAStoltzRRKisickiJPharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteersJ Clin Pharmacol20004041042010761169
   PubMed Web of Science ®Google Scholar
• MorrisPEJrElliottAJWaltonSPWilliamsCHMontgomeryJASynthesis and biological activity of a novel class of purine nucleoside phosphorylase inhibitorsNucleosides Nucleotides Nucleic Acids20001937940410772722
   PubMed Web of Science ®Google Scholar
• ConryRMBantiaSTurnerHSEffects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cellsImmunopharmacology199840199776473
   PubMed Web of Science ®Google Scholar
• BantiaSMillerPJParkerCDPurine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) – a novel potent and orally active immunosuppressive agentInt Immunopharmacol200111199121011407314
   PubMed Web of Science ®Google Scholar
• KilpatrickJMMorrisPESerotaDGJrIntravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2′-deoxyguanosine in primatesInt Immunopharmacol2003354154812689658
   PubMed Web of Science ®Google Scholar
• KicskaGALongLHörigHImmucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytesProc Natl Acad Sci U S A2001984593459811287638
   PubMed Web of Science ®Google Scholar
• Al-KaliAGandhiVAyoubiMKeatingMRavandiFForodesine: review of preclinical and clinical dataFuture Oncol201061211121720799866
   PubMed Web of Science ®Google Scholar
• GandhiVKilpatrickJMPlunkettWA proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forode-sine)Blood20051064253426016131572
   PubMed Web of Science ®Google Scholar
• FurmanRRGoreLRavandiFHoelzerDForodesine IV (Bcx-1777) is clinically active in relapsed/refractory T-cell leukemia: results of a phase II study (interim report)Blood20061081851 Abstract
   Web of Science ®Google Scholar
• DuvicMForero-TorresAFossFOlsenEKimYResponse to oral forodesine in refractory cutaneous T-cell lymphoma: interim results of a phase I/II studyBlood2007110122 Abstract
   Web of Science ®Google Scholar
• DummerRDuvicMScarisbrickJFinal results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome)Ann Oncol2014251807181224948692
   PubMed Web of Science ®Google Scholar
• OguraMTsukasakiKNagaiHPhase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignanciesCancer Sci20121031290129522448814
   PubMed Web of Science ®Google Scholar
• TsukasakiKTobinaiKUchidaTPhase 1/2 study of forodesine in patients with relapsed peripheral T-cell lymphoma (PTCL)J Clin Oncol2016347542 Abstract
   Web of Science ®Google Scholar
• ShibayamaHTobinaiKTsukasakiKUpdated report of a phase I/II multicenter study of forodesine, a purine nucleoside phosphorylase inhibitor, in Japanese patients with relapsed peripheral T-cell lymphomaASH 59th Annual Meeting and ExpositionDecember 9–12, 2017Atlanta, GA Abstract#4075
   Google Scholar
• ChesonBDPfistnerBJuweidMERevised response criteria for malignant lymphomaJ Clin Oncol20072557958617242396
   PubMed Web of Science ®Google Scholar